CSI Market
Sign In | Register

Zevra Therapeutics Inc (ZVRA) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ZVRA quarterly Cash Flow →
This page allows investors to follow Zevra Therapeutics Inc's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income83.23
Depreciation & amortization4.05
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Intangible Assets, Finite-lived58.71
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase10.38
Research and Development in Process0.00
Gain (Loss) on Disposition of Intangible Assets-148.33
Share-based Compensation12.63
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction4.20
Current Portion Of Convertible Notes-
Deferred Offering Costs Writeoff-
Increase Decrease In Operating Lease Rightofuse Asset-
Loss On Sublease And Disposal Of Property And Equipment0.06
Fair Value Adjustment Of Investments-0.15
Income Tax Expense Benefit Noncash Adjustment3.45
Increase Decrease In Discount And Rebate Liabilities6.68
Fair Value Adjustment Related To Warrant And C V R Liability-2.18
Gain On Sale Of Priority Review Voucher-
Discount And Rebate Liabilities-
Fair Value Adjustment Related To Derivative Instrument-0.68
Cash Paid To Settle Derivative Instrument And Payoff Premium-
Payment Of Paid In Kind Interest-
Consulting Fees Paid In Common Stock-
Increase Decrease In Operating Lease Right Of Use Asset-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts and Other Receivables-11.98
Accounts Payable-15.59
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.94
Other Working Capital-0.71
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-2.45
Discontinued operations0.00
Net Cash flow from Operating Activities-1.60
Investing Activities
Capital Expenditures-0.84
Sale of Capital Items0.45
Payments for (Proceeds from) Investments0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Sale Of Priority Review Voucher150.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments-131.49
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Payments to Acquire Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities18.13
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock11.82
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.62
Proceeds From Underwritten Public Offering Net-
Finance Lease Principal Payments-
Proceeds From Insurance Financing Arrangements-
Proceeds From Employee Stock Purchase Plan-
Payments Of Principal On Insurance Financing Arrangements-0.37
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities12.06
Effect of exchange rate on cash flow0.03
Discontinued operations0.00
Free Cash Flow-1.98
Total Cash Flow28.62
4 historic quarters locked

Sign in to unlock the full Zevra Therapeutics Inc cash flow history.

Sign In Create Free Account

About Zevra Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001434647-26-000011

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License